Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × pembrolizumab × Clear all
NCT06137144 2026-05-19

PRIMAVERA

AstraZeneca

Phase 1/2 Recruiting
161 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Dana-Farber Cancer Institute

Phase 2 Completed
82 enrolled 20 charts
Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

Columbia University

Phase 2 Recruiting
53 enrolled
DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale University

Phase 2 Recruiting
32 enrolled
DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 1/2 Terminated
17 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡